DEF: Vyome Holdings to Vote on New Equity Plan, Directors

Vyome Holdings, Inc. announced its 2025 Annual Meeting of Stockholders to vote on director elections, a new equity incentive plan, auditor ratification, and executive compensation.

Summary

• The 2025 Annual Meeting of Stockholders will be held on October 28, 2025, at 12:00 p.m., Eastern Time, in New York.
• Shareholders will vote on the election of Krishna K. Gupta, Shiladitya Sengupta, and Stash Pomichter as Class I directors, each to serve until the 2028 annual meeting.
• A proposal to approve the Vyome Holdings, Inc. 2025 Equity Incentive Plan will be voted on, which makes 2,000,000 shares of common stock available for issuance, with annual increases thereafter.
• Shareholders will vote on the ratification of Kreit & Chiu CPA LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, following the dismissal of Haskell & White LLP on August 18, 2025.
• An advisory vote on the compensation of named executive officers for the fiscal year ended December 31, 2024, will also take place.
• The record date for stockholders entitled to vote is September 17, 2025, with 5,493,751 shares of common stock issued and outstanding, held by 98 record holders.
• The Board of Directors unanimously recommends a vote FOR all nominees for director, FOR the 2025 Equity Incentive Plan, FOR the auditor ratification, and FOR the advisory resolution on executive compensation.

Sentiment

Score: 4

Explanation: While the company is making strategic moves with a new board, executive team, and an AI Committee, the historical financial reporting issues, including 'substantial doubt about the Company's ability to continue as a going concern' and 'material weaknesses in internal control over financial reporting,' present significant concerns. The frequent change in auditors also raises red flags. The new equity plan is a positive for talent retention but also implies potential dilution.

Positives

• The 2025 Equity Incentive Plan is proposed to attract, motivate, retain, and reward executives and other employees, officers, directors, consultants, and service providers with competitive incentives tied to stockholder value.
• A new, experienced Board of Directors and executive team were appointed following the merger, bringing diverse expertise in technology, healthcare, venture capital, and corporate growth.
• An Artificial Intelligence (AI) Committee has been established, comprising members with deep AI expertise, to evaluate opportunities, prioritize projects, oversee data strategy, and advise on AI-related risks in healthcare, biotech, and medtech.
• The company has adopted robust corporate governance policies, including a code of business conduct and ethics, an insider trading policy, and anti-hedging/anti-pledging policies.

Negatives

• Previous auditor reports (RSM US LLP for fiscal years ended December 31, 2023, and 2022) contained an emphasis of matter paragraph related to "substantial doubt about the Company's ability to continue as a going concern."
• Material weaknesses in the Company's internal control over financial reporting were reported for fiscal years ended December 31, 2023, and 2022.
• The company experienced significant turnover in its independent registered public accounting firms, dismissing RSM US LLP on April 8, 2024, and Haskell & White LLP on August 18, 2025, before appointing Kreit & Chiu CPA LLP.
• Late Section 16(a) reports were filed by a beneficial owner of more than 10% of common stock and a former executive officer (Thomas Stankovich) in 2024.

Risks

• Substantial doubt about the Company's ability to continue as a going concern, as noted by the former independent auditor for fiscal years 2023 and 2022.
• Material weaknesses in the Company's internal control over financial reporting, as previously reported for fiscal years 2023 and 2022.
• Forward-looking statements are subject to risks, uncertainties, and other factors described in the 'Risk Factors' section of the 2024 Annual Report and other SEC filings, which could cause actual results to differ materially.

Future Outlook

The company is seeking approval for the 2025 Equity Incentive Plan to attract and retain key talent, which is seen as a significant factor for future performance and growth. The establishment of an Artificial Intelligence (AI) Committee signals a strategic focus on evaluating and prioritizing AI opportunities within healthcare, biotech, and medtech, aiming to drive innovation and growth in these frontier industries.

Management Comments

• "It is my pleasure to invite you to attend the 2025 Annual Meeting of Stockholders." Venkat Nelabhotla, Chief Executive Officer.
• "We urge you to read and consider these documents carefully. We look forward to your engagement with the Annual Meeting." Venkat Nelabhotla, Chief Executive Officer.
• "Our board of directors believes that an adequate reserve of shares available for issuance under the Plan is necessary to enable us to attract, motivate, retain and reward executives and other employees, officers, directors, consultants and other persons who provide services to us through the use of competitive incentives that are tied to stockholder value." (Regarding the 2025 Equity Incentive Plan).

Industry Context

Vyome Holdings, Inc. operates in the pharmaceuticals, biotech, and consumer products industries, with a recent merger and a new strategic emphasis on Artificial Intelligence (AI) applications in healthcare and medtech. The reconstituted board and executive team bring extensive experience from these sectors and venture capital, aligning the company with broader industry trends of digital transformation and technology integration in life sciences. The formation of a dedicated AI Committee positions the company to actively pursue innovation and competitive advantage in a rapidly evolving technological landscape.

Comparison to Industry Standards

• Director compensation is designed to be competitive with that provided by comparably-sized, publicly-traded, medical device companies, although specific benchmarks or companies are not detailed.
• The 2025 Equity Incentive Plan is intended to provide competitive incentives to attract and retain talent, a common practice in high-growth sectors like biotech and technology.
• The company's strategic focus on AI applications in healthcare, biotech, and medtech aligns with a significant industry trend, where major players and startups are investing heavily in AI for drug discovery, diagnostics, and personalized medicine, such as Google Health or various venture-backed AI health tech companies.

Management Changes

Corporate Governance

Related Party Transactions

• Dr. Shiladitya Sengupta, a post-Merger director, has a consulting agreement with Vyome Therapeutics, Inc. (VTI) since January 1, 2019, entitling him to a fee of $100,000 per annum. He also received stock awards of VTI amounting to $151,939 in the fiscal year ended December 31, 2024.

Stakeholder Impact

• Shareholders will directly influence corporate governance through their votes on director elections, the new equity incentive plan, and auditor ratification. The historical 'going concern' and internal control issues may impact investor confidence and share value.
• Employees and executives are positively impacted by the proposed 2025 Equity Incentive Plan, designed to attract, motivate, retain, and reward them, aligning their interests with shareholder value. New leadership appointments signify a refreshed strategic direction.
• Regulatory bodies will monitor the company's compliance with SEC requirements, especially given past late Section 16(a) reports and reported material weaknesses in internal controls, requiring diligent adherence to governance policies.

Next Steps

• Hold the 2025 Annual Meeting of Stockholders on October 28, 2025, for shareholder votes on the proposed agenda items.
• Publish final voting results in a Current Report on Form 8-K with the SEC within four business days following the Annual Meeting.
• The Board of Directors and Compensation Committee will consider the outcome of the advisory vote on executive compensation when making future compensation decisions.
• The Audit Committee will reconsider whether to retain Kreit & Chiu CPA LLP if stockholders fail to ratify their appointment.
• The 2025 Equity Incentive Plan will see an annual increase in available shares starting on the first day of the company's fiscal year beginning in 2026.
• Stockholders interested in presenting a proposal for inclusion in the proxy statement for the 2026 annual meeting must submit it by June 30, 2026.
• Stockholders intending to present a proposal or nominate a director at the 2026 annual meeting (not for proxy statement inclusion) must provide written notice between July 15, 2026, and August 14, 2026.

Key Dates

Recommendation

While Vyome Holdings has undergone a significant merger, reconstituted its board with experienced individuals, and is strategically focusing on AI, the historical issues of 'substantial doubt about the Company's ability to continue as a going concern' and 'material weaknesses in internal control over financial reporting' are serious concerns. The frequent auditor changes also add to the uncertainty. The new equity plan is a positive for talent, but the overall financial health and control environment need to demonstrate sustained improvement before a more positive recommendation can be made. Investors should hold and monitor the company's progress in addressing these fundamental issues and executing its new strategy.

Keywords

Vyome Holdings, Proxy Statement, Annual Meeting, Director Election, Equity Incentive Plan, Auditor Ratification, Executive Compensation, Corporate Governance, AI Committee, Financial Reporting, Internal Controls, Biotech, Pharmaceuticals, Medical Device, Venture Capital